End-of-day quote
Korea S.E.
06:00:00 2024-05-30 pm EDT
|
5-day change
|
1st Jan Change
|
47,000
KRW
|
+4.68%
|
|
-6.93%
|
-6.56%
|
Fiscal Period: December |
2023
|
---|
Capitalization
1 |
403,531
|
Enterprise Value (EV)
1 |
386,587
|
P/E ratio
|
-35.8
x
|
Yield
|
-
|
Capitalization / Revenue
|
59.4
x
|
EV / Revenue
|
57
x
|
EV / EBITDA
|
-44.9
x
|
EV / FCF
|
-104
x
|
FCF Yield
|
-0.96%
|
Price to Book
|
7.63
x
|
Nbr of stocks (in thousands)
|
8,022
|
Reference price
2 |
50,300
|
Announcement Date
|
3/20/24
|
Fiscal Period: December |
2023
|
---|
Net sales
1 |
6,788
|
EBITDA
1 |
-8,605
|
EBIT
1 |
-10,557
|
Operating Margin
|
-155.53%
|
Earnings before Tax (EBT)
1 |
-10,211
|
Net income
1 |
-10,040
|
Net margin
|
-147.92%
|
EPS
2 |
-1,406
|
Free Cash Flow
1 |
-3,723
|
FCF margin
|
-54.85%
|
FCF Conversion (EBITDA)
|
-
|
FCF Conversion (Net income)
|
-
|
Dividend per Share
|
-
|
Announcement Date
|
3/20/24
|
Fiscal Period: December |
2023
|
---|
Net Debt
1 |
-
|
Net Cash position
1 |
16,944
|
Leverage (Debt/EBITDA)
|
-
|
Free Cash Flow
1 |
-3,723
|
ROE (net income / shareholders' equity)
|
-20.8%
|
ROA (Net income/ Total Assets)
|
-12.4%
|
Assets
1 |
80,974
|
Book Value Per Share
2 |
6,591
|
Cash Flow per Share
2 |
2,232
|
Capex
1 |
212
|
Capex / Sales
|
3.12%
|
Announcement Date
|
3/20/24
|
|
1st Jan change
|
Capi.
|
---|
| -6.56% | 273M | | -38.56% | 8.39B | | +0.18% | 3.32B | | +9.29% | 2.48B | | -18.21% | 2.06B | | -24.57% | 1.59B | | +32.37% | 1.15B | | -7.64% | 704M | | +8.42% | 678M | | -29.59% | 508M |
Bio Diagnostics & Testing
|